Examen
Page URL: https://www.bionews.org.uk/page_94213

Down's syndrome chromosome 'can be silenced'

22 July 2013
Appeared in BioNews 714

A method of 'switching off' entire chromosomes has been used in isolated cells to target the genetic defect behind Down's syndrome.

The proof-of-principle study opens a new avenue of research into the cell pathways underlying Down's syndrome. Although similar techniques have been used in cells to target defective genes, this is the first time that the effects of a whole extra chromosome have been blocked.

Scientists from the University of Massachusetts, led by Professor Jeanne Lawrence, took a gene that naturally acts to inactivate spare X chromosomes in female mammals and used it to inactivate chromosome 21.

X chromosome inactivation typically silences one of the two X chromosomes in all genetically female individuals to prevent the damaging effects of a double dose of X chromosome genes. The X chromosome gene XIST produces many RNA molecules that coat the spare chromosome, preventing genes being switched on. Professor Lawrence's team used 'genomeediting' techniques to cut and paste the XIST gene into chromosome 21, allowing it to be effectively silenced.

By switching off one copy of chromosome 21 in cells from a donor with Down's syndrome, otherwise identical cultures of the Down's syndrome cells with and without silencing of the extra chromosome could be compared. Subtle differences in cell function caused by the active extra chromosome were observed for the first time.

Most people have 23 pairs of chromosomes, including two sex chromosomes. People with Down's syndrome are born with three copies of chromosome 21, rather than two, and have variable learning difficulties, a greater risk of heart and immune defects, and early-onset Alzheimer's disease. There are around 750 children born with Down's syndrome each year in the UK.

Professor Lawrence said: 'Our hope is that for individuals living with Down's syndrome, this proof-of-principle opens up multiple exciting new avenues for studying the disorder now.'

SOURCES & REFERENCES
Down's syndrome cells 'fixed' in first step towards chromosome therapy
The Guardian |  17 July 2013
Genetic advance in Down's syndrome
BBC News |  17 July 2013
Scientists close to 'switching off' Down's syndrome gene
The Telegraph |  17 July 2013
Scientists Show Proof-Of-Principle for Silencing Extra Chromosome Responsible for Down Syndrome
Science Daily (press release) |  17 July 2013
Translating dosage compensation to trisomy 21
Nature |  17 July 2013
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
24 July 2017 - by Helen Robertson 
US scientists have identified a new mechanism by which genes are silenced, or 'imprinted' during early embryonic development...
4 November 2013 - by María Victoria Rivas Llanos 
A new method for prenatal testing for Down's syndrome will be tried out at Great Ormond Street Hospital for Children (GOSH), London....
10 June 2013 - by James Brooks 
A test using only a blood sample taken from a pregnant woman is more reliable than current checks in indicating the likelihood of Down's syndrome, say researchers...
24 October 2011 - by Julianna Photopoulos 
A new prenatal test that can detect Down's syndrome by using a sample of the mother's blood was launched in twenty US cities last Monday....
17 January 2011 - by Owen Clark 
New research suggests that Down's syndrome could be detected using genetic screening, avoiding the need for invasive detection procedures....
23 November 2009 - by Dr Will Fletcher 
A new drug that is being developed may lessen the effects of learning difficulties caused by the genetic condition Down's syndrome. Children with the condition are not developmentally delayed at birth, but often fall behind as they grow older because of memory deficits. A new study in mice, published in the journal Science Translational Medicine, has identified the key brain defects responsible and has pointed out a strategy for dealing with them through medication. The US resea...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.